{
    "code": "10000874",
    "許可證字號": "衛署菌疫輸字第000874號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "有效日期": "108\/01\/19",
    "發證日期": "98\/01\/19",
    "許可證種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA01000087408",
    "中文品名": "癌思停 注射劑 (瑞士廠)",
    "英文品名": "Avastin Injection",
    "適應症": "適應症變更\r\n1. 轉移性大腸直腸癌(mCRC)\r\nAvastin(Bevacizumab)與含有irinotecan\/5-fluorouracil\/Leucovorin或\r\n5-fluorouracil\/Leucovorin 之化學療法合併使用，可作為轉移性\r\n大腸或直腸癌患者之第一線治療。\r\nAvastin與含有5-fluorouracil\/Leucovorin\/Oxaliplatin之化學療法合併\r\n使用，可作為先前接受過以Fluoropyrimidine為基礎之化學療法\r\n無效且未曾接受過Avastin治療之轉移性大腸或直腸癌患者之治療。\r\nAvastin與含有Fluoropyrimidine-oxaliplatin之化學療法合併使用，\r\n可作為第一線已接受過Avastin併用Fluoropyrimidine-irinotecan\r\n為基礎之化療後惡化之轉移性大腸或直腸癌患者之第二線治療。\r\n\r\n2. 轉移性乳癌(mBC)\r\nAvastin與Paclitaxel合併使用，可作為HER2 (-)轉移性乳癌患者\r\n之第一線治療。\r\n\r\n3. 惡性神經膠質瘤(WHO第4級) - 神經膠母細胞瘤\r\nAvastin 單獨使用可用於治療曾接受標準放射線治療且含\r\nTemozolomide 在內之化學藥物治療失敗之多型性神經膠母細胞瘤\r\n(Glioblastoma Multiforme)復發之成人患者。\r\n\r\n4. 晚期、轉移性或復發性非鱗狀非小細胞肺癌(NSCLC)\r\nAvastin與Carbolatin及Paclitaxel合併使用，可作為無法切除之\r\n晚期、轉移性或復發性非小細胞肺癌患者之第一線治療。",
    "劑型": "270注射劑",
    "包裝": "4毫升小瓶裝 16毫升小瓶裝 100小瓶以下盒裝",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "主成分略述": "BEVACIZUMAB",
    "限制項目": [
        "02輸入"
    ],
    "申請商名稱": "1901701100  羅氏大藥廠股份有限公司",
    "申請商地址": "台北市松山區民生東路三段１３４號９樓",
    "主製造廠": {
        "製造廠名稱": "F430257000  F. HOFFMANN-LA ROCHE LTD.",
        "製造廠廠址": "WURMISWEG, CH-4303 KAISERAUGST, SWITZERLAND",
        "製造廠公司地址": "",
        "製造廠國別": "SWITZERLAND",
        "製程": ""
    },
    "CCC號列": "",
    "藥理治療分類": "",
    "次製造廠": [
        {
            "製造廠名稱": "F430258000  F. HOFFMANN-LA ROCHE LTD.",
            "製造廠廠址": "GRENZACHERSTRASSE 124, CH-4070 BASEL, SWITZERLAND",
            "製造廠公司地址": "",
            "製造廠國別": "SWITZERLAND",
            "製程": "bulk"
        },
        {
            "製造廠名稱": "F460768000  GENENTECH, INC.",
            "製造廠廠址": "1 ANTIBODY WAY, OCEANSIDE, CA 92056, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "bulk"
        }
    ],
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000800",
            "成分名稱": "BEVACIZUMAB",
            "含量描述": "",
            "含量": "25.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "仿單 100008740001-103-08-22.pdf 100008740001-102-07-18.pdf 100008740002___20110711.pdf 100008740002___20100923.pdf 100008740002___20100609.pdf 100008740001___20110711.pdf 100008740001___20100923.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/(S(knoy1cz5iwyfatvvguaez0re))\/ShowFile.aspx?LicId=10000874&Seq=007&Type=9"
        },
        {
            "title": "外盒 100008740007-102-07-18.pdf 100008740006-102-07-18.pdf 100008740005-102-07-18.pdf 100008740004-102-07-18.pdf 100008740003-102-07-18.pdf 100008740002-102-07-18.pdf",
            "url": "http:\/\/www.fda.gov.tw\/MLMS\/(S(knoy1cz5iwyfatvvguaez0re))\/ShowFile.aspx?LicId=10000874&Seq=006&Type=8"
        }
    ]
}